Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA-approved for fluid and electrolyte replacement,Treatment of dehydration,Maintenance of fluid and electrolyte balance,Used as a vehicle for intravenous drug administration (off-label),Correction of hyponatremia (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose: not applicable (endogenous substrate); glucose half-life ~1.5–2 hours in circulation under normal conditions, prolonged in hyperglycemia. Sodium chloride: not applicable as ions are electrolytes with no elimination half-life; renal clearance depends on glomerular filtration and tubular reabsorption.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose undergoes glycolysis and subsequent metabolism via the tricarboxylic acid cycle. Sodium and chloride are primarily excreted unchanged by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Dextrose is fully metabolized to carbon dioxide and water; no significant renal excretion of intact dextrose. Sodium chloride is excreted renally; sodium and chloride ions are eliminated via kidneys, with excretion proportional to intake and renal function. No biliary or fecal elimination of intact components.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: not bound to plasma proteins. Sodium chloride: sodium and chloride ions are not protein-bound (<1% bound).
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: ~0.2 L/kg (distributes in extracellular fluid). Sodium: ~0.2–0.3 L/kg (mainly extracellular). Chloride: ~0.2–0.3 L/kg. Clinical meaning: Vd approximates extracellular fluid volume; expansion of Vd indicates fluid overload.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% for both dextrose and sodium chloride. Not administered by other routes.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific renal dose adjustment; use caution in renal impairment due to sodium load. Monitor fluid status. GFR <30 m L/min: consider reduced rate or use of alternative fluids.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific hepatic adjustment required. Use standard dosing; monitor for fluid overload in severe hepatic impairment (Child-Pugh C).
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based: 5-10 m L/kg/dose as maintenance fluid, administered at 100-150 m L/kg/day for infants and 60-80 m L/kg/day for older children, adjusted per clinical need.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower end of infusion rate (50 m L/hour) and titrate based on renal function and cardiac status. Monitor for hyperglycemia and fluid overload due to reduced renal function and comorbidities.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of fluid overload, especially in patients with heart failure, renal impairment, or edema,Hyperglycemia in diabetic patients or those with glucose intolerance,Hypersensitivity reactions (rare),Electrolyte disturbances (e.g., hypernatremia, hyponatremia, hyperchloremia) with improper use,Not for use in patients with increased intracranial pressure or severe renal impairment without careful monitoring
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia with severe dehydration,Intracranial or intraspinal hemorrhage (when used as a vehicle),Severe electrolyte disturbances without correction,Allergy to dextrose or sodium chloride
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions, but patients should avoid high-sodium foods to prevent hypernatremia.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimester: No risk.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Compatible with breastfeeding. Dextrose and sodium chloride are normal constituents of breast milk. M/P ratio not applicable as they are endogenous substances. No adverse effects expected.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment required. Pregnancy does not significantly alter the pharmacokinetics of dextrose or sodium chloride. Dosing is based on clinical need for fluid and electrolyte replacement.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This solution is isotonic (308 m Osm/L) and provides 170 kcal/L from dextrose. It is contraindicated in patients with hyperglycemia, hypernatremia, or fluid overload. Use with caution in renal impairment, heart failure, or elderly patients. Monitor serum glucose, sodium, and volume status. Do not administer if solution is discolored or contains particulates.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Inform your healthcare provider if you have diabetes, high blood pressure, or heart failure.,Tell your doctor if you experience headache, swelling, shortness of breath, or dry mouth.,This medication provides sugar and salt; avoid additional sodium in your diet unless directed.,Report any pain, redness, or swelling at the IV site.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimeste. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.